{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T08:10:49Z","timestamp":1789459849780,"version":"build-2803163510"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["VR 2015-03295"],"award-info":[{"award-number":["VR 2015-03295"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1007\/s00228-018-2448-y","type":"journal-article","created":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T03:12:32Z","timestamp":1522120352000},"page":"903-911","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["N-Acetyltransferase-2 (NAT2) phenotype is influenced by genotype-environment interaction in Ethiopians"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9788-0790","authenticated-orcid":false,"given":"Eleni","family":"Aklillu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Antonio","family":"Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyasu","family":"Makonnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leif","family":"Bertilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasa","family":"Djordjevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"issue":"11","key":"2448_CR1","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1111\/bph.12598","volume":"171","author":"E Sim","year":"2014","unstructured":"Sim E, Abuhammad A, Ryan A (2014) Arylamine N-acetyltransferases: from drug metabolism and pharmacogenetics to drug discovery. Br J Pharmacol 171(11):2705\u20132725. \n                    https:\/\/doi.org\/10.1111\/bph.12598","journal-title":"Br J Pharmacol"},{"key":"2448_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/1471-2156-9-21","volume":"9","author":"A Sabbagh","year":"2008","unstructured":"Sabbagh A, Langaney A, Darlu P, Gerard N, Krishnamoorthy R, Poloni ES (2008) Worldwide distribution of NAT2 diversity: implications for NAT2 evolutionary history. BMC Genet 9:21. \n                    https:\/\/doi.org\/10.1186\/1471-2156-9-21","journal-title":"BMC Genet"},{"issue":"10","key":"2448_CR3","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1177\/0091270011420261","volume":"52","author":"N Djordjevic","year":"2012","unstructured":"Djordjevic N, Carrillo JA, Roh HK, Karlsson S, Ueda N, Bertilsson L, Aklillu E (2012) Comparison of N-acetyltransferase-2 enzyme genotype-phenotype and xanthine oxidase enzyme activity between Swedes and Koreans. J Clin Pharmacol 52(10):1527\u20131534. \n                    https:\/\/doi.org\/10.1177\/0091270011420261","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"2448_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.2217\/pgs.11.122","volume":"13","author":"DW Hein","year":"2012","unstructured":"Hein DW, Doll MA (2012) Accuracy of various human NAT2 SNP genotyping panels to infer rapid, intermediate and slow acetylator phenotypes. Pharmacogenomics 13(1):31\u201341. \n                    https:\/\/doi.org\/10.2217\/pgs.11.122","journal-title":"Pharmacogenomics"},{"issue":"8","key":"2448_CR5","doi-asserted-by":"publisher","first-page":"851","DOI":"10.2217\/pgs.12.48","volume":"13","author":"G Suarez-Kurtz","year":"2012","unstructured":"Suarez-Kurtz G, Vargens DD, Sortica VA, Hutz MH (2012) Accuracy of NAT2 SNP genotyping panels to infer acetylator phenotypes in African, Asian, Amerindian and admixed populations. Pharmacogenomics 13(8):851\u2013854; author reply 855. \n                    https:\/\/doi.org\/10.2217\/pgs.12.48","journal-title":"Pharmacogenomics"},{"issue":"8","key":"2448_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/fpc.0000000000000062","volume":"24","author":"EM McDonagh","year":"2014","unstructured":"McDonagh EM, Boukouvala S, Aklillu E, Hein DW, Altman RB, Klein TE (2014) PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2. Pharmacogenet Genomics 24(8):409\u2013425. \n                    https:\/\/doi.org\/10.1097\/fpc.0000000000000062","journal-title":"Pharmacogenet Genomics"},{"issue":"2","key":"2448_CR7","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/sj.ejhg.5201963","volume":"16","author":"H Magalon","year":"2008","unstructured":"Magalon H, Patin E, Austerlitz F, Hegay T, Aldashev A, Quintana-Murci L, Heyer E (2008) Population genetic diversity of the NAT2 gene supports a role of acetylation in human adaptation to farming in Central Asia. Eur J Hum Genet 16(2):243\u2013251. \n                    https:\/\/doi.org\/10.1038\/sj.ejhg.5201963","journal-title":"Eur J Hum Genet"},{"key":"2448_CR8","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s12862-015-0543-6","volume":"15","author":"E Podgorna","year":"2015","unstructured":"Podgorna E, Diallo I, Vangenot C, Sanchez-Mazas A, Sabbagh A, Cerny V, Poloni ES (2015) Variation in NAT2 acetylation phenotypes is associated with differences in food-producing subsistence modes and ecoregions in Africa. BMC Evol Biol 15:263. \n                    https:\/\/doi.org\/10.1186\/s12862-015-0543-6","journal-title":"BMC Evol Biol"},{"issue":"4","key":"2448_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018507","volume":"6","author":"A Sabbagh","year":"2011","unstructured":"Sabbagh A, Darlu P, Crouau-Roy B, Poloni ES (2011) Arylamine N-acetyltransferase 2 (NAT2) genetic diversity and traditional subsistence: a worldwide population survey. PLoS One 6(4):e18507. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0018507","journal-title":"PLoS One"},{"key":"2448_CR10","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-nutr-080508-141048","volume":"30","author":"F Luca","year":"2010","unstructured":"Luca F, Perry GH, Di Rienzo A (2010) Evolutionary adaptations to dietary changes. Annu Rev Nutr 30:291\u2013314. \n                    https:\/\/doi.org\/10.1146\/annurev-nutr-080508-141048","journal-title":"Annu Rev Nutr"},{"key":"2448_CR11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12863-015-0212-1","volume":"16","author":"C Valente","year":"2015","unstructured":"Valente C, Alvarez L, Marks SJ, Lopez-Parra AM, Parson W, Oosthuizen O, Oosthuizen E, Amorim A, Capelli C, Arroyo-Pardo E, Gusmao L, Prata MJ (2015) Exploring the relationship between lifestyles, diets and genetic adaptations in humans. BMC Genet 16:55. \n                    https:\/\/doi.org\/10.1186\/s12863-015-0212-1","journal-title":"BMC Genet"},{"issue":"9","key":"2448_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003136","volume":"3","author":"F Luca","year":"2008","unstructured":"Luca F, Bubba G, Basile M, Brdicka R, Michalodimitrakis E, Rickards O, Vershubsky G, Quintana-Murci L, Kozlov AI, Novelletto A (2008) Multiple advantageous amino acid variants in the NAT2 gene in human populations. PLoS One 3(9):e3136. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0003136","journal-title":"PLoS One"},{"issue":"7","key":"2448_CR13","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1177\/0091270010377630","volume":"51","author":"N Djordjevic","year":"2011","unstructured":"Djordjevic N, Carrillo J, Ueda N, Gervasini G, Fukasawa T, Suda A, Jankovic S, Aklillu E (2011) N-acetyltransferase-2 (NAT2) gene polymorphisms and enzyme activity in Serbs: unprecedented high prevalence of rapid acetylators in a white population. J Clin Pharmacol 51(7):994\u20131003. \n                    https:\/\/doi.org\/10.1177\/0091270010377630","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"2448_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/ahg.12198","volume":"81","author":"MM Al-Ahmad","year":"2017","unstructured":"Al-Ahmad MM, Amir N, Dhanasekaran S, John A, Abdulrazzaq YM, Ali BR, Bastaki S (2017) Studies on N-Acetyltransferase (NAT2) genotype relationships in Emiratis: confirmation of the existence of phenotype variation among slow acetylators. Ann Hum Genet 81(5):190\u2013196. \n                    https:\/\/doi.org\/10.1111\/ahg.12198","journal-title":"Ann Hum Genet"},{"issue":"7","key":"2448_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1177\/0091270006288955","volume":"46","author":"RJ Straka","year":"2006","unstructured":"Straka RJ, Burkhardt RT, Lang NP, Hadsall KZ, Tsai MY (2006) Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. J Clin Pharmacol 46(7):802\u2013811. \n                    https:\/\/doi.org\/10.1177\/0091270006288955","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2448_CR16","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1007\/s00204-004-0622-8","volume":"79","author":"HM Bolt","year":"2005","unstructured":"Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K (2005) Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol 79(4):196\u2013200. \n                    https:\/\/doi.org\/10.1007\/s00204-004-0622-8","journal-title":"Arch Toxicol"},{"issue":"9\u201310","key":"2448_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s002280000203","volume":"56","author":"B Zhao","year":"2000","unstructured":"Zhao B, Seow A, Lee EJ, Lee HP (2000) Correlation between acetylation phenotype and genotype in Chinese women. Eur J Clin Pharmacol 56(9\u201310):689\u2013692","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"2448_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1177\/00970002042006004","volume":"42","author":"WM O\u2019Neil","year":"2002","unstructured":"O\u2019Neil WM, MacArthur RD, Farrough MJ, Doll MA, Fretland AJ, Hein DW, Crane LR, Svensson CK (2002) Acetylator phenotype and genotype in HIV-infected patients with and without sulfonamide hypersensitivity. J Clin Pharmacol 42(6):613\u2013619","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2448_CR19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001809","volume":"3","author":"G Yimer","year":"2008","unstructured":"Yimer G, Aderaye G, Amogne W, Makonnen E, Aklillu E, Lindquist L, Yamuah L, Feleke B, Aseffa A (2008) Anti-tuberculosis therapy-induced hepatotoxicity among Ethiopian HIV-positive and negative patients. PLoS One 3(3):e1809. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0001809","journal-title":"PLoS One"},{"issue":"7","key":"2448_CR20","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/j.bcp.2008.07.024","volume":"76","author":"JE Muscat","year":"2008","unstructured":"Muscat JE, Pittman B, Kleinman W, Lazarus P, Stellman SD, Richie JP Jr (2008) Comparison of CYP1A2 and NAT2 phenotypes between black and white smokers. Biochem Pharmacol 76(7):929\u2013937. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2008.07.024","journal-title":"Biochem Pharmacol"},{"issue":"7484","key":"2448_CR21","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature12820","volume":"505","author":"LA David","year":"2014","unstructured":"David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA, Biddinger SB, Dutton RJ, Turnbaugh PJ (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505(7484):559\u2013563. \n                    https:\/\/doi.org\/10.1038\/nature12820","journal-title":"Nature"},{"key":"2448_CR22","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.trsl.2016.08.002","volume":"179","author":"ID Wilson","year":"2017","unstructured":"Wilson ID, Nicholson JK (2017) Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res 179:204\u2013222. \n                    https:\/\/doi.org\/10.1016\/j.trsl.2016.08.002","journal-title":"Transl Res"},{"issue":"3","key":"2448_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.5507\/bp.2016.039","volume":"160","author":"L Jourova","year":"2016","unstructured":"Jourova L, Anzenbacher P, Anzenbacherova E (2016) Human gut microbiota plays a role in the metabolism of drugs. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 160(3):317\u2013326. \n                    https:\/\/doi.org\/10.5507\/bp.2016.039","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"issue":"6","key":"2448_CR24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2174\/138920008784892155","volume":"9","author":"E Garcia-Martin","year":"2008","unstructured":"Garcia-Martin E (2008) Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. Curr Drug Metab 9(6):487\u2013497","journal-title":"Curr Drug Metab"},{"issue":"9","key":"2448_CR25","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1093\/infdis\/jit352","volume":"208","author":"JG Pasipanodya","year":"2013","unstructured":"Pasipanodya JG, McIlleron H, Burger A, Wash PA, Smith P, Gumbo T (2013) Serum drug concentrations predictive of pulmonary tuberculosis outcomes. J Infect Dis 208(9):1464\u20131473. \n                    https:\/\/doi.org\/10.1093\/infdis\/jit352","journal-title":"J Infect Dis"},{"issue":"18","key":"2448_CR26","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.2217\/pgs.15.144","volume":"16","author":"J Shi","year":"2015","unstructured":"Shi J, Xie M, Wang J, Xu Y, Liu X (2015) Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis. Pharmacogenomics 16(18):2083\u20132097. \n                    https:\/\/doi.org\/10.2217\/pgs.15.144","journal-title":"Pharmacogenomics"},{"issue":"12","key":"2448_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0027810","volume":"6","author":"G Yimer","year":"2011","unstructured":"Yimer G, Ueda N, Habtewold A, Amogne W, Suda A, Riedel KD, Burhenne J, Aderaye G, Lindquist L, Makonnen E, Aklillu E (2011) Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One 6(12):e27810. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0027810","journal-title":"PLoS One"},{"issue":"5","key":"2448_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.5588\/ijtld.11.0377","volume":"16","author":"PY Wang","year":"2012","unstructured":"Wang PY, Xie SY, Hao Q, Zhang C, Jiang BF (2012) NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis 16(5):589\u2013595. \n                    https:\/\/doi.org\/10.5588\/ijtld.11.0377","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"2448_CR29","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1128\/AAC.49.5.1733-1738.2005","volume":"49","author":"M Kinzig-Schippers","year":"2005","unstructured":"Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sorgel F, Fuhr U (2005) Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49(5):1733\u20131738. \n                    https:\/\/doi.org\/10.1128\/AAC.49.5.1733-1738.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"2448_CR30","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00228-007-0305-5","volume":"63","author":"PR Donald","year":"2007","unstructured":"Donald PR, Parkin DP, Seifart HI, Schaaf HS, van Helden PD, Werely CJ, Sirgel FA, Venter A, Maritz JS (2007) The influence of dose and N-acetyltransferase-2 (NAT2) genotype and phenotype on the pharmacokinetics and pharmacodynamics of isoniazid. Eur J Clin Pharmacol 63(7):633\u2013639. \n                    https:\/\/doi.org\/10.1007\/s00228-007-0305-5","journal-title":"Eur J Clin Pharmacol"},{"key":"2448_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.toxrep.2016.10.004","volume":"3","author":"A Toure","year":"2016","unstructured":"Toure A, Cabral M, Niang A, Diop C, Garat A, Humbert L, Fall M, Diouf A, Broly F, Lhermitte M, Allorge D (2016) Prevention of isoniazid toxicity by NAT2 genotyping in Senegalese tuberculosis patients. Toxicol Rep 3:826\u2013831. \n                    https:\/\/doi.org\/10.1016\/j.toxrep.2016.10.004","journal-title":"Toxicol Rep"},{"issue":"5","key":"2448_CR32","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s00228-012-1429-9","volume":"69","author":"J Azuma","year":"2013","unstructured":"Azuma J, Ohno M, Kubota R, Yokota S, Nagai T, Tsuyuguchi K, Okuda Y, Takashima T, Kamimura S, Fujio Y, Kawase I, Pharmacogenetics-based tuberculosis therapy research g (2013) NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy. Eur J Clin Pharmacol 69(5):1091\u20131101. \n                    https:\/\/doi.org\/10.1007\/s00228-012-1429-9","journal-title":"Eur J Clin Pharmacol"},{"key":"2448_CR33","unstructured":"World Health Organization (2017) Global tuberculosis report 2017. WHO, Geneva, 262 p. Available from: \n                    http:\/\/www.who.int\/tb\/publications\/global_report\/en\/"},{"issue":"1","key":"2448_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1186\/s12864-016-3078-3","volume":"17","author":"Z Petros","year":"2016","unstructured":"Petros Z, Lee MM, Takahashi A, Zhang Y, Yimer G, Habtewold A, Amogne W, Aderaye G, Schuppe-Koistinen I, Mushiroda T, Makonnen E, Kubo M, Aklillu E (2016) Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity. BMC Genomics 17(1):755. \n                    https:\/\/doi.org\/10.1186\/s12864-016-3078-3","journal-title":"BMC Genomics"},{"issue":"2","key":"2448_CR35","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/tpj.2010.16","volume":"11","author":"E Gebeyehu","year":"2011","unstructured":"Gebeyehu E, Engidawork E, Bijnsdorp A, Aminy A, Diczfalusy U, Aklillu E (2011) Sex and CYP3A5 genotype influence total CYP3A activity: high CYP3A activity and a unique distribution of CYP3A5 variant alleles in Ethiopians. Pharmacogenomics J 11(2):130\u2013137. \n                    https:\/\/doi.org\/10.1038\/tpj.2010.16","journal-title":"Pharmacogenomics J"},{"issue":"9","key":"2448_CR36","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1089\/omi.2016.0119","volume":"20","author":"E Aklillu","year":"2016","unstructured":"Aklillu E, Habtewold A, Ngaimisi E, Yimer G, Mugusi S, Amogne W, Reuter T, Meid A, Hoffmann MM, Weiss J (2016) SLCO1B1 gene variations among Tanzanians, Ethiopians, and Europeans: relevance for African and worldwide precision medicine. OMICS 20(9):538\u2013545. \n                    https:\/\/doi.org\/10.1089\/omi.2016.0119","journal-title":"OMICS"},{"issue":"7","key":"2448_CR37","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1182\/blood-2008-01-135863","volume":"111","author":"E Aklillu","year":"2008","unstructured":"Aklillu E, Leong C, Loebstein R, Halkin H, Gak E (2008) VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111(7):3903\u20133904. \n                    https:\/\/doi.org\/10.1182\/blood-2008-01-135863","journal-title":"Blood"},{"issue":"6","key":"2448_CR38","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1038\/tpj.2012.46","volume":"13","author":"A Habtewold","year":"2013","unstructured":"Habtewold A, Amogne W, Makonnen E, Yimer G, Nylen H, Riedel KD, Aderaye G, Bertilsson L, Burhenne J, Diczfalusy U, Aklillu E (2013) Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients. Pharmacogenomics J 13(6):484\u2013489. \n                    https:\/\/doi.org\/10.1038\/tpj.2012.46","journal-title":"Pharmacogenomics J"},{"issue":"5","key":"2448_CR39","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1097\/00008571-200207000-00005","volume":"12","author":"E Aklillu","year":"2002","unstructured":"Aklillu E, Herrlin K, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M (2002) Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden. Pharmacogenetics 12(5):375\u2013383","journal-title":"Pharmacogenetics"},{"issue":"7","key":"2448_CR40","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00228-003-0653-8","volume":"59","author":"E Aklillu","year":"2003","unstructured":"Aklillu E, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M (2003) Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol 59(7):533\u2013536. \n                    https:\/\/doi.org\/10.1007\/s00228-003-0653-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"2448_CR41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/omi.2013.0140","volume":"18","author":"E Aklillu","year":"2014","unstructured":"Aklillu E, Djordjevic N, Carrillo JA, Makonnen E, Bertilsson L, Ingelman-Sundberg M (2014) High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population. OMICS 18(7):446\u2013453. \n                    https:\/\/doi.org\/10.1089\/omi.2013.0140","journal-title":"OMICS"},{"issue":"4","key":"2448_CR42","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1097\/00007691-200008000-00008","volume":"22","author":"JA Carrillo","year":"2000","unstructured":"Carrillo JA, Christensen M, Ramos SI, Alm C, Dahl ML, Benitez J, Bertilsson L (2000) Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine. Ther Drug Monit 22(4):409\u2013417","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2448_CR43","first-page":"125","volume":"11","author":"A Anitha","year":"2003","unstructured":"Anitha A, Banerjee M (2003) Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med 11(1):125\u2013131","journal-title":"Int J Mol Med"},{"issue":"6","key":"2448_CR44","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/j.1365-2125.1989.tb03558.x","volume":"28","author":"PR Jackson","year":"1989","unstructured":"Jackson PR, Tucker GT, Woods HF (1989) Testing for bimodality in frequency distributions of data suggesting polymorphisms of drug metabolism--hypothesis testing. Br J Clin Pharmacol 28(6):655\u2013662","journal-title":"Br J Clin Pharmacol"},{"key":"2448_CR45","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/2193-1801-1-34","volume":"1","author":"E Varshney","year":"2012","unstructured":"Varshney E, Saha N, Tandon M, Shrivastava V, Ali S (2012) Prevalence of poor and rapid metabolizers of drugs metabolized by CYP2B6 in North Indian population residing in Indian national capital territory. Spring 1:34. \n                    https:\/\/doi.org\/10.1186\/2193-1801-1-34","journal-title":"Spring"},{"issue":"1\u20132","key":"2448_CR46","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.cca.2006.08.010","volume":"376","author":"HP Rihs","year":"2007","unstructured":"Rihs HP, John A, Scherenberg M, Seidel A, Bruning T (2007) Concordance between the deduced acetylation status generated by high-speed: real-time PCR based NAT2 genotyping of seven single nucleotide polymorphisms and human NAT2 phenotypes determined by a caffeine assay. Clin Chim Acta 376(1\u20132):240\u2013243. \n                    https:\/\/doi.org\/10.1016\/j.cca.2006.08.010","journal-title":"Clin Chim Acta"},{"issue":"2","key":"2448_CR47","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/00008571-199604000-00003","volume":"6","author":"U Fuhr","year":"1996","unstructured":"Fuhr U, Rost KL, Engelhardt R, Sachs M, Liermann D, Belloc C, Beaune P, Janezic S, Grant D, Meyer UA, Staib AH (1996) Evaluation of caffeine as a test drug for CYP1A2, NAT2 and CYP2E1 phenotyping in man by in vivo versus in vitro correlations. Pharmacogenetics 6(2):159\u2013176","journal-title":"Pharmacogenetics"},{"issue":"3\u20134","key":"2448_CR48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0731-7085(01)00656-2","volume":"28","author":"P Wong","year":"2002","unstructured":"Wong P, Villeneuve G, Tessier V, Banerjee K, Nedev H, Jean-Claude BJ, Leyland-Jones B (2002) Stability of 5-acetamido-6-formylamino-3-methyluracil in buffers and urine. J Pharm Biomed Anal 28(3\u20134):693\u2013700","journal-title":"J Pharm Biomed Anal"},{"issue":"1","key":"2448_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1046\/j.1365-2125.2003.01730.x","volume":"55","author":"A Nyeki","year":"2003","unstructured":"Nyeki A, Buclin T, Biollaz J, Decosterd LA (2003) NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol 55(1):62\u201367","journal-title":"Br J Clin Pharmacol"},{"key":"2448_CR50","doi-asserted-by":"publisher","unstructured":"Brenmoehl J, Walz C, Spitschak M, Wirthgen E, Walz M, Langhammer M, Tuchscherer A, Naumann R, Hoeflich A (2017) Partial phenotype conversion and differential trait response to conditions of husbandry in mice. J Comp Physiol B. \n                    https:\/\/doi.org\/10.1007\/s00360-017-1138-x","DOI":"10.1007\/s00360-017-1138-x"},{"issue":"3","key":"2448_CR51","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1124\/mol.64.3.659","volume":"64","author":"E Aklillu","year":"2003","unstructured":"Aklillu E, Carrillo J, Makonnen E, Hellman K, Pitarque M, Bertilsson L, Ingelman-Sundberg M (2003) Genetic polymorphism of CYP1A2 in ethiopians affecting induction and expression: characterization of novel haplotypes with single-nucleotide polymorphisms in intron 1. Mol Pharmacol 64(3):659\u2013669. \n                    https:\/\/doi.org\/10.1124\/mol.64.3.659","journal-title":"Mol Pharmacol"},{"issue":"6","key":"2448_CR52","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/tpj.2015.72","volume":"16","author":"R Bisso-Machado","year":"2016","unstructured":"Bisso-Machado R, Ramallo V, Paixao-Cortes VR, Acuna-Alonzo V, Demarchi DA, Sandoval JR, Granara AA, Salzano FM, Hunemeier T, Bortolini MC (2016) NAT2 gene diversity and its evolutionary trajectory in the Americas. Pharmacogenomics J 16(6):559\u2013565. \n                    https:\/\/doi.org\/10.1038\/tpj.2015.72","journal-title":"Pharmacogenomics J"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-018-2448-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-018-2448-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T20:17:19Z","timestamp":1553631439000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-018-2448-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":52,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["2448"],"URL":"https:\/\/doi.org\/10.1007\/s00228-018-2448-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"15 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Human Ethics Committees at Huddinge University Hospital, Karolinska Institutet, Stockholm, Sweden and the National Ethics committees at Ethiopian Science and Technology Commission, Addis Ababa, Ethiopia.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have conflict no interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}